{
    "nct_id": "NCT04099251",
    "official_title": "A Phase 3, Randomized, Double-Blind Study of Adjuvant Immunotherapy With Nivolumab Versus Placebo After Complete Resection of Stage IIB/C Melanoma",
    "inclusion_criteria": "* Had a negative sentinel lymph node biopsy\n* Participant has not been previously treated for melanoma\n* ECOG 0 or 1\n* Participants must have been diagnosed with histologically confirmed, Resected, Stage IIB/C cutaneous melanoma\nHealthy volunteers allowed\nMust have minimum age of 12 Years",
    "exclusion_criteria": "* History of ocular or mucosal melanoma.\n* Pregnant or nursing women\n* Participants with active known or suspected autoimmune disease\n* Known history of allergy or hypersensitivity to study drug components\n* Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, anti-CTLA-4 antibody, or agents that target IL-2 pathways, T-cell stimulators, or checkpoint pathways\n\nOther protocol defined inclusion/exclusion criteria apply.",
    "miscellaneous_criteria": ""
}